Gang An
YOU?
Author Swipe
View article: Monoclonal gammopathy defines distinct clinical subsets in Chronic Lymphocytic Leukemia across therapeutic eras
Monoclonal gammopathy defines distinct clinical subsets in Chronic Lymphocytic Leukemia across therapeutic eras Open
Monoclonal gammopathy (MG) in chronic lymphocytic leukemia (CLL) portends heterogeneous outcomes, yet its molecular drivers and therapeutic implications remain undefined. In this retrospective analysis of 2,075 CLL patients (1999-2024), MG…
View article: Correlation between the expression of soluble BCMA and short-term/long-term curative effect and survival outcomes of anti-BCMA CAR-T cell therapy in relapsed/refractory multiple myeloma
Correlation between the expression of soluble BCMA and short-term/long-term curative effect and survival outcomes of anti-BCMA CAR-T cell therapy in relapsed/refractory multiple myeloma Open
This study aimed to investigate whether soluble B-cell maturation antigen (sBCMA) levels could be predictive biomarker for short-term and long-term therapeutic efficacy and survival outcomes following anti-BCMA CAR-T cell therapy in relaps…
View article: Development of a Cytogenetic Double-Hit Model for Survival Prediction in Multiple Myeloma
Development of a Cytogenetic Double-Hit Model for Survival Prediction in Multiple Myeloma Open
Background: High-risk chromosomal abnormalities (HRCAs) detected by fluorescence in situ hybridization (FISH) have a well-established adverse prognostic impact in multiple myeloma (MM). It is increasingly recognized that the coexistence of…
View article: Development and validation of a prognostic staging system for primary plasma cell leukemia
Development and validation of a prognostic staging system for primary plasma cell leukemia Open
View article: Identification of a CAR‐Derived Clone by <scp>NGS</scp>‐Based <scp>MRD</scp> After Fully Human <scp>BCMA CAR</scp> T‐Cell Therapy in Multiple Myeloma
Identification of a CAR‐Derived Clone by <span>NGS</span>‐Based <span>MRD</span> After Fully Human <span>BCMA CAR</span> T‐Cell Therapy in Multiple Myeloma Open
View article: Real-world outcomes of isatuximab with pomalidomide and dexamethasone for relapsed and/or refractory multiple myeloma
Real-world outcomes of isatuximab with pomalidomide and dexamethasone for relapsed and/or refractory multiple myeloma Open
Background: The isatuximab, pomalidomide, and dexamethasone (Isa-Pd) regimen has shown survival benefits for relapsed and/or refractory multiple myeloma (RRMM) in several trials, while evidence of effectiveness and safety among Chinese pat…
View article: Supplemental Table 5 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
Supplemental Table 5 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study Open
Supplemental Table 5. Factors associated with progression.
View article: Supplemental Table 6 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
Supplemental Table 6 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study Open
Supplemental Table 6. The outcomes and disease status of patients who completed the treatment.
View article: Supplemental Figure 6 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
Supplemental Figure 6 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study Open
Supplemental Figure 6. Swim lane plots of efficacy in patients treated with ZID.
View article: Supplemental Figure 4 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
Supplemental Figure 4 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study Open
Supplemental Figure 4. Change of lymphocyte subsets before and after treatment.
View article: Supplementary Data 1 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
Supplementary Data 1 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study Open
Inclusion and exclusion criteria, Exclusion criteria, Treatment termination criteria and exclusion criteria, Case exclusion criteria, General combined medication and supportive care
View article: Supplemental Figure 1 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
Supplemental Figure 1 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study Open
Supplemental Figure 1. Schematic diagram of the research scheme.
View article: Supplemental Figure 2 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
Supplemental Figure 2 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study Open
Supplemental Figure 2. Treatment flow chart.
View article: Supplemental Table 4 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
Supplemental Table 4 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study Open
Supplemental Table 4. Factors associated with deep response rate after induction and at best response.
View article: Supplemental Figure 5 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
Supplemental Figure 5 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study Open
Supplemental Figure 5. Survival outcomes in patients with or without deep remission.
View article: Supplemental Figure 3 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
Supplemental Figure 3 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study Open
Supplemental Figure 3. Mutations and immunoglobulin heavy chain variable (IGHV) fragments of patients.
View article: Supplementary Table 1 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
Supplementary Table 1 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study Open
Supplementary Table 1. Representativeness of Study Participants.
View article: Supplemental Table 2 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
Supplemental Table 2 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study Open
Supplemental Table 2.The modified criteria from IWWM-6.
View article: Supplemental Table 3 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
Supplemental Table 3 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study Open
Supplemental Table 3.The results of chromosome karyotype in all the patients.
View article: Data from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
Data from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study Open
Purpose:Waldenström macroglobulinemia (WM) is a rare type of lymphoma, with no optimal treatment. Bruton’s tyrosine kinase inhibitors have shown promising outcomes, yet achieving deep remission (very good partial remission or complete remi…
View article: Health-related quality of life with daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible patients with newly diagnosed multiple myeloma: analysis of the phase 3 OCTANS study
Health-related quality of life with daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible patients with newly diagnosed multiple myeloma: analysis of the phase 3 OCTANS study Open
View article: The specific transcriptional profile and clonal selection of monoclonal gammopathy of undetermined significance-like behavior predict an exceptionally favorable prognosis in multiple myeloma
The specific transcriptional profile and clonal selection of monoclonal gammopathy of undetermined significance-like behavior predict an exceptionally favorable prognosis in multiple myeloma Open
Not available.
View article: A novel indirubin- 3-monoxime derivative I3MV- 8b exhibits remarkable cytotoxicity against multiple myeloma by targeting TRIM28
A novel indirubin- 3-monoxime derivative I3MV- 8b exhibits remarkable cytotoxicity against multiple myeloma by targeting TRIM28 Open
View article: Continuous R-DA-EDOCH alternated with high-dose Ara-C induces deep remission and overcomes high-risk factors in young patients with newly diagnosed mantle cell lymphoma
Continuous R-DA-EDOCH alternated with high-dose Ara-C induces deep remission and overcomes high-risk factors in young patients with newly diagnosed mantle cell lymphoma Open
Objective: Our previous studies have indicated potentially higher proliferative activity of tumor cells in Chinese patients with mantle-cell lymphoma (MCL) than those in Western. Given the success and tolerability of R-DA-EDOCH immunochemo…
View article: Thalidomide-based regimen shows promising efficacy in large granular lymphocytic leukemia: a multicenter phase II study
Thalidomide-based regimen shows promising efficacy in large granular lymphocytic leukemia: a multicenter phase II study Open
Large granular lymphocytic leukemia (LGLL) is characterized by the clonal proliferation of cytotoxic T lymphocytes or NK cells. Standard first-line immunosuppressive treatments have limitations, achieving complete remission (CR) rates of u…
View article: Classification of NK-large granular lymphocytic leukemia by CD56 expression
Classification of NK-large granular lymphocytic leukemia by CD56 expression Open
NK-large granular lymphocytic leukemia (NK-LGLL) is a rare chronic lymphoproliferative disorder and displays heterogeneity that remains insufficiently defined. CD56 plays a pivotal role in NK-cell maturation linked to cytotoxicity. However…
View article: The optimal time and clinical implications of measurable residual disease detection in mantle cell lymphoma
The optimal time and clinical implications of measurable residual disease detection in mantle cell lymphoma Open
Recent advances in measurable residual disease (MRD) technology have significantly enhanced predictive accuracy for outcomes in various hematologic malignancies, serving as a crucial surrogate endpoint. However, in mantle cell lymphoma (MC…
View article: Whole-genome sequencing identifies novel loci for keratoconus and facilitates risk stratification in a Han Chinese population
Whole-genome sequencing identifies novel loci for keratoconus and facilitates risk stratification in a Han Chinese population Open
Background Keratoconus (KC) is a prevalent corneal condition with a modest genetic basis. Recent studies have reported significant genetic associations in multi-ethnic cohorts. However, the situation in the Chinese population remains unkno…
View article: LGR4 promotes proliferation and homing via activation of the NF‑κB signaling pathway in multiple myeloma
LGR4 promotes proliferation and homing via activation of the NF‑κB signaling pathway in multiple myeloma Open
Multiple myeloma (MM) is a plasma cell malignancy characterized by clonal proliferation in the bone marrow (BM). Previously, it was reported that G‑protein‑coupled receptor 4 (LGR4) contributed to early hematopoiesis and was associated wit…
View article: Targeting <i>Enterobacter cloacae</i> attenuates osteolysis by reducing ammonium in multiple myeloma
Targeting <i>Enterobacter cloacae</i> attenuates osteolysis by reducing ammonium in multiple myeloma Open
Multiple myeloma (MM)-induced bone disease affects not only patients’ quality of life but also their overall survival. Our previous work demonstrated that the gut microbiome plays a crucial role in MM progression and drug resistance. Howev…